Autopsy report · NCT02304289

Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in Patients With Hepatocellular Carcinoma

“slow recruitment of patients”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 1 month before it stopped.
• 2 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

University Hospital, Ghent

Sponsor type

University, hospital or other

Conditions

Hepatocellular Carcinoma

Interventions

Artesunate

Participants

2

Sites

1

Countries

Belgium

Trials that died the same way

• A Pilot Study of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma
  “slow patient recruitment” (95% match in meaning)
• Evaluation of the Parietex TM Parastomal No Hole Mesh for Repair of Parastomal Hernias in End-colostomies
  “too slow patiënts recruitment” (94% match in meaning)
• Bosentan for Treatment of Hepatopulmonary Syndrome in Patients With Liver Cirrhosis
  “too slow patient recruitment” (90% match in meaning)
• Growth Hormone in Poor Responders to IVF Trial
  “Insufficient/slow patient recruitment” (89% match in meaning)
• TPF Followed by Cetuximab and IMRT Plus Carbon Ion Boost for Locally Advanced Head and Neck Tumors
  “slow recruitment (only 8 patients recruited and treated until 12/2012)” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.